Schizophrenia-relevant behaviors in a genetic mouse model of constitutive Nurr1 deficiency
Authors:
Open Access
- 4 May 2011
- journal article
- Published by Wiley in Genes, Brain and Behavior
- Vol. 10 (5) , 589-603
Abstract
Nurr1 (NR4A2) is an orphan nuclear receptor highly essential for the dopaminergic development and survival. Altered expression of Nurr1 has been suggested as a potential genetic risk factor for dopamine‐related brain disorders, including schizophrenia. In support of this, recent experimental work in genetically modified mice shows that mice with a heterozygous constitutive deletion of Nurr1 show a facilitation of the development of schizophrenia‐related behavioral abnormalities. However, the behavioral characterization of this Nurr1‐deficient mouse model remains incomplete. This study therefore used a comprehensive behavioral test battery to evaluate schizophrenia‐relevant phenotypes in Nurr1‐deficient mice. We found that these mice displayed increased spontaneous locomotor activity and potentiated locomotor reaction to systemic treatment with the non‐competitive N‐methyl‐d‐aspartate (NMDA) receptor antagonist, dizocilpine (MK‐801). In addition, male but not female Nurr1‐deficient mice showed significant deficits in the prepulse inhibition and prepulse‐elicited reactivity. However, Nurr1 deletion did not induce overt abnormalities in other cardinal behavioral and cognitive functions known to be impaired in schizophrenia, including social interaction and recognition, spatial recognition memory or discrimination reversal learning. Our findings thus suggest that heterozygous constitutive deletion of Nurr1 results in a restricted phenotype characteristic of schizophrenia symptomatology, which primarily relates to motor activity, sensorimotor gating and responsiveness to the psychomimetic drug MK‐801. This study further emphasizes a critical role of altered dopaminergic development in the precipitation of specific brain dysfunctions relevant to human psychotic disorder.Keywords
This publication has 62 references indexed in Scilit:
- Single‐Dose Administration of MK‐0657, an NR2B‐Selective NMDA Antagonist, Does Not Result in Clinically Meaningful Improvement in Motor Function in Patients With Moderate Parkinson's DiseaseThe Journal of Clinical Pharmacology, 2009
- Nurr1 in Parkinson's disease and related disordersJournal of Comparative Neurology, 2005
- Importance of Animal Models in Schizophrenia ResearchAustralian & New Zealand Journal of Psychiatry, 2005
- Recognition of Visual Stimuli and Memory for Spatial Context in Schizophrenic Patients and Healthy VolunteersJournal of Clinical and Experimental Neuropsychology, 2004
- Elevated locomotor activity without altered striatal dopamine contents in Nurr1 heterozygous mice after acute exposure to methamphetamineBehavioural Brain Research, 2003
- NURR1 promoter polymorphisms: Parkinson's disease, schizophrenia, and personality traitsAmerican Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2003
- Rodent models of prefrontal cortical functionTrends in Neurosciences, 2002
- Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studiesPsychopharmacology, 2001
- NURR1 Mutations in cases of schizophrenia and manic-depressive disorderAmerican Journal of Medical Genetics, 2000
- Gating and Habituation of the Startle Reflex in Schizophrenic PatientsArchives of General Psychiatry, 1992